UNMIRI launches oncology literature intelligence platform

UNMIRI LLC has launched a literature intelligence and key-opinion-leader platform for oncology medical affairs teams, with a free trial now live and paid plans for individuals, teams, and enterprises. The product is built to help biotech and pharma teams track research, surface cited summaries, and manage KOL workflows with source-linked outputs.

Why it matters: - Oncology medical affairs teams spend much of their time tracking publications, abstracts, guideline changes, and the experts behind them. - UNMIRI is targeting teams in biotech and pharma that need research monitoring and KOL workflows built for medical affairs, not generic literature tools. - The platform is positioned for groups that need cited, traceable outputs instead of uncited summaries.

What happened: - UNMIRI LLC launched a literature intelligence and key-opinion-leader platform for oncology medical affairs teams. - The platform is live now, and users can sign up at the company's announcement, start a free trial without a sales call, and run a first watch list the same day. - Paid plans are available for individual users, teams, and enterprise workspaces.

The details: - Watch lists can be built by gene, variant, drug, or topic. - The platform sends digests that explain what changed and why it matters. - Search is variant-aware, so a query such as EGFR L858R in lung cancer expands across variant name forms used in PubMed and related tumor synonyms. - Results are ranked by recency, citation count, study type, direct relevance to the query, and whether the article already appears in curated knowledge bases such as CIViC and ClinVar. - Full text is pulled only from open-access articles whose licenses permit it, while other sources contribute abstracts. - Summaries are generated by a language model under strict rules and are labeled as machine-generated. - Every claim in a summary must cite the PubMed IDs behind it. - A verbatim guard paraphrases output rather than copying text. - A second model pass checks each claim against its cited sources and removes unsupported statements. - Each claim carries a confidence label tied to the strength of the evidence, so a Phase 3 readout and a case report do not look equivalent. - The output is reference material for professionals, not clinical advice. - The KOL workflow layer lets teams log interactions with key opinion leaders, generate call plans for MSL visits, prepare advisory-board briefing documents based on each expert's publications, and track medical inquiries through resolution. - Teams that use Salesforce can connect the inquiry workflow optionally. - Team and enterprise workspaces share watch lists, inquiry queues, and KOL history across seats.

Between the lines: - UNMIRI is trying to serve the middle market of medical affairs teams that need more specialized tooling than broad literature platforms and less cost and complexity than enterprise-only systems. - The product leans heavily on source traceability, which may appeal to teams that need defensible workflows in regulated environments. - The combination of watch lists and KOL tooling suggests UNMIRI wants to move from passive monitoring to day-to-day field operations.

What's next: - UNMIRI says the platform is one of several surfaces on its precision oncology platform. - That broader platform also includes cross-vendor NGS interpretation, genomics-aware clinical decision support, variant-grounded trial matching, and prior-authorization decisions. - The free trial is open now at the signup page.

The bottom line: - UNMIRI is betting that oncology medical affairs teams will pay for literature intelligence that is source-linked, variant-aware, and tied directly to KOL workflows.